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ABSTRACT
A previous limited study demonstrated that Mycobacterium tuberculosis isolates with a mutation at
amino-acid position 315 of katG (D315) exhibited high-level resistance to isoniazid and were more
frequently resistant to streptomycin. In the present study, isoniazid-resistant M. tuberculosis isolates
from 8332 patients in The Netherlands (1993–2002) were screened for the D315 mutation. Isoniazid
resistance was found in 592 (7%) isolates, of which 323 (55%) carried D315. IS6110 restriction fragment
length polymorphism analysis showed that D315 isolates occurred in clusters, suggesting recent
transmission, at the same frequency as isoniazid-susceptible isolates. In contrast, other isoniazid-
resistant isolates clustered significantly less frequently. D315 isolates were high-level isoniazid-resistant,
streptomycin-resistant and multidrug-resistant significantly more often, and may have a greater impact
on public health, than other isoniazid-resistant isolates.
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INTRODUCTION
Despite the availability of various drugs with
activity against Mycobacterium tuberculosis and
worldwide bacille Calmette–Gue´rrin vaccination,
tuberculosis (TB) is the second most frequent
infectious cause of death worldwide [1]. The
emergence of drug resistance, and especially
multidrug resistance (i.e., resistance to at least
isoniazid and rifampicin), among strains of
M. tuberculosis has become a major health threat
in various parts of the world [2]. One of the
mainstay drugs for the treatment of TB is isoni-
azid. Its effectiveness against M. tuberculosis was
discovered simultaneously by three groups in
1952 [3–5], but resistant strains were reported
shortly thereafter [6]. In The Netherlands, an
isoniazid resistance level of 7% was reached in
1993–1997 [7], but resistance levels of up to 30–
40% have been reached in several high-incidence
countries [8].
Resistance against isoniazid is associated
mostly with mutations or deletions in katG.
This gene encodes the enzyme catalase peroxi-
dase, which converts isoniazid into an active
compound (isoniazid itself has no mycobacteri-
cidal activity) [9–11]. Other resistance mutations
occur in the inhA gene (or its promoter), which
encodes an enoyl acyl carrier protein reductase
involved in fatty acid synthesis, which is the
Corresponding author and reprint requests: H. R. van Doorn,
Academic Medical Center, Department of Medical Microbio-
logy, Room L1-245, Meibergdreef 9, 1105AZ Amsterdam,
The Netherlands
E-mail: h.r.vandoorn@amc.uva.nl
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases
target of the active derivative of isoniazid [12].
Mutations in several other genes have been
reported to be associated with isoniazid resist-
ance, but occur less frequently, and their associ-
ation with isoniazid resistance is less clear [13].
The most frequent mutation occurs at amino-acid
position 315 of katG (D315), and this mutation
accounts for 53–96% of resistance mutations
among isoniazid-resistant isolates [7,14–18].
Part of the success of the D315 isolates is
probably caused by the fact that catalase peroxi-
dase is still active in these mutants; indeed, 30–
40% of the initial catalase activity remains when
this mutation is introduced into katG with site-
directed mutagenesis [19]. A previous study in
The Netherlands revealed that D315 isolates were
found in clusters as frequently as isoniazid-
susceptible isolates, whereas isoniazid-resistant
isolates with another mechanism of resistance
appeared to be transmitted less frequently (reflec-
ted by a lower percentage of clustered isolates).
However, these differences were not significant.
Furthermore, D315 isolates were reported to be
associated significantly with high-level resistance
to isoniazid and with additional streptomycin
resistance [7].
In the present study, the prevalence of the D315
mutation was determined among 8332 M. tuber-
culosis isolates sent to the National Institute of
Public Health and the Environment (RIVM, Bil-
thoven, The Netherlands) between 1993 and 2002.
The associations between the presence of this
mutation and other laboratory and clinical data
were examined to determine the significance of
the basis of isoniazid resistance in relation to the
potential impact on public health.
MATERIALS AND METHODS
Between 1993 and 2002, c.10 000 isolates of M. tuberculosis
from TB patients in The Netherlands were submitted to the
RIVM for species identification, drug susceptibility testing and
IS6110 restriction fragment length polymorphism (RFLP)
typing [20,21]. Patient information was obtained from The
Netherlands Tuberculosis Register, maintained by the
KNCV Tuberculosis Foundation, which has been in place
since 1993. The Netherlands Tuberculosis Register lists patient
information anonymously; therefore, patient information was
matched with laboratory information, using gender, date of
birth, postal area code and year of diagnosis to identify
matches.
The susceptibility of all isolates to isoniazid, streptomycin
and rifampicin was determined with the MIC method [22],
testing concentrations of 0.1, 0.5, 1, 2, 5, 10, 20 and 50 mg ⁄L in
7H10 medium (Difco, Detroit, MI, USA). The isolates were
considered to be resistant if > 1% of the original inoculum
grew on concentrations of at least 0.5, 10 and 2 mg ⁄L for
isoniazid, streptomycin and rifampicin, respectively. Multi-
drug resistance was defined, according to the definition of the
WHO, as resistance to at least isoniazid and rifampicin.
Isoniazid-resistant isolates were investigated for the pres-
ence of the D315 mutation by PCR restriction endonuclease
analysis with either AciI [17] or MspA1I [23] for the isolates
obtained in 1993–1997, or by DNA sequencing of a 127-bp
fragment of katG, using primers 315MGB-s and 315MGB-as
[24], for the isolates obtained in 1998–2002. On the basis of
these assays, the isoniazid-resistant isolates were divided into
two groups: those with the D315 mutation, and other isoniazid-
resistant isolates.
Standard RFLP typing was performed with IS6110 as a
probe [21]. If fewer than five bands were present in the RFLP
pattern, polymorphic GC-rich sequence RFLP typing was also
performed [20]. The term ‘cluster’ was used for two or more
M. tuberculosis isolates with completely identical RFLP pat-
terns, or for the respective patients. Based on IS6110 RFLP
analysis or spoligotyping, isolates were assigned to the Beijing
genotype according to international guidelines [25].
ORs were calculated with the Epi6 program (CDC, Atlanta,
GA, USA). Binary logistic regression to adjust for possible
confounders (all variables were taken into account) was
performed with SPSS v.11.5.2 software (SPSS Inc., Chicago,
IL, USA).
RESULTS
During the period 1993–2002, c.15 000 cases of TB
were recorded in The Netherlands. Bacteria
belonging to the M. tuberculosis complex were
cultured from c.10 000 cases and were submitted
to the RIVM [26]. Laboratory data from the RIVM
were matched successfully with clinical data from
the Netherlands Tuberculosis Register for 8332
patients. For these patients, all variables were
known, except the results of microscopy (3495;
42%) and data concerning previous episodes of TB
(7305; 88%). Of the 8332 patients, 592 (7.1%)
yielded isoniazid-resistant M. tuberculosis, and 74
(0.89%) yielded multidrug-resistant (MDR)
M. tuberculosis. PCR analysis showed that 323
isoniazid-resistant isolates (55%) had the D315
mutation, and of these, 95% had an isoniazid MIC
> 2 mg ⁄L. In contrast, only 14% of isoniazid-
resistant isolates without this mutation had an
MIC > 2 mg ⁄L. Among all isoniazid-resistant iso-
lates with an MIC > 2 mg ⁄L, 89% had the D315
mutation (Fig. 1).
Because of the different characteristics of iso-
lates from Dutch patients and immigrants, the
dataset was split into Dutch (n = 3437; 41%) and
non-Dutch (n = 4895; 59%) patients. The countries
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of origin of the non-Dutch patients were central
and eastern Europe (n = 283; 6%), Turkey
(n = 398; 8%), Morocco (n = 752; 15%), Somalia
(n = 1156; 24%), other African countries (n = 887;
18%), Asia (n = 1009; 21%) and other countries
(n = 410; 8%). Similarities among these groups
were observed in terms of age group composition
and resistance to all tested anti-TB agents (the
highest resistance rates were found among central
and eastern European patients), in contrast to
Dutch patients. Striking differences were: the rate
of clustering was higher among Somalian and
Moroccan patients (62%), but lower among Asian
patients (24%); the prevalence of the Beijing strain
was highest among Asian patients (18% vs. 3%);
and a large proportion of Somalian patients
presented with non-pulmonary TB (59% vs. 31%).
In general, as a group, non-Dutch patients
suffered less frequently from pulmonary TB, had
fewer positive smears, and were less frequently
clustered; they yielded more isoniazid-resistant,
rifampicin-resistant, streptomycin-resistant or
MDR M. tuberculosis isolates, and were infected
more frequently with a D315 isolate (Table 1).
Furthermore, the age distribution differed
between Dutch and non-Dutch patients (Fig. 2).
Differences in age group, smear positivity, clus-
tering and resistance to rifampicin, isoniazid and
streptomycin were associated independently with
Dutch or non-Dutch nationality (Table 1).
Among Dutch patients, isoniazid-resistant
M. tuberculosis was associated with a different
age distribution (with a higher prevalence among
patients aged < 45 years; data not shown) and
with co-resistance to streptomycin and rifampi-
cin. Isoniazid-resistant M. tuberculosis among
non-Dutch patients was associated with a previ-
ous episode of TB, a positive Ziehl–Neelsen-
stained smear, infection with an isolate belonging
to the Beijing lineage, and resistance to strepto-
mycin and to rifampicin. Independent co-variates
of isoniazid resistance among non-Dutch patients
were a pulmonary localisation, clustering, and
streptomycin and rifampicin resistance (Table 2).
D315 isolates were obtained from 40 (36%) of
111 isoniazid-resistant Dutch cases, and from 283
(59%) of 481 isoniazid-resistant non-Dutch cases
(OR 0.39, 95% CI 0.25–0.62). Among Dutch
patients with isoniazid-resistant isolates, the
presence of D315 isolates was associated with a
pulmonary localisation and streptomycin resist-
ance; among non-Dutch patients, the presence of
D315 isolates was associated with clustering,
streptomycin resistance and MDR (Table 3).
Associations between the different mutations
that were found, namely AGC (Ser) to ACC (Thr),
ACA (Thr), ACG (Thr), ATC (Ile) or AAC (Asn),
and the clinical and laboratory data could not be
assessed. More than 95% of all mutations were
AGC to ACC. Therefore, the numbers of isolates
with other mutations were too small to allow
conclusions.
DISCUSSION
This study shows that more than half of all
isoniazid-resistant M. tuberculosis isolates from
patients in The Netherlands have a mutation at
amino-acid position 315 of katG. This mutation
appeared to be associated with three important
factors: first, high levels of drug resistance, with
89% of all isolates with an isoniazid MIC
‡ 5 mg ⁄L carrying this mutation; second, D315
isolates from Dutch and non-Dutch patients were
more often co-resistant to streptomycin, and D315
isolates from non-Dutch patients to rifampicin
(i.e., MDR), than non-D315 isoniazid-resistant
isolates (Table 3); third, among non-Dutch
patients, isoniazid-resistant D315 isolates were
associated with an increased transmission risk
(or an increased progression from infection to
disease), as reflected by a greater percentage of
clustered D315 isolates compared to non-D315
isoniazid-resistant isolates. This association was
strongest among Somalian patients (OR 3.67,
Fig. 1. Association between the MIC of isoniazid and a
mutation at amino-acid 315 of katG in Mycobacterium
tuberculosis isolates.
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95% CI 1.57–8.65) and other African patients
(OR 2.45, not significant), but was absent among
Moroccan and Asian patients (not significant).
Whereas isoniazid-resistant isolates in general
were less clustered than isoniazid-susceptible
isolates, D315 isolates were clustered as fre-
quently as isoniazid-susceptible isolates (Table 3).
A possible relationship between this mutation
and transmissibility was also suggested in an
earlier study [7], but the differences in clustering
were not significant. Among Dutch patients in the
present study, increased clustering was also
observed, but this was again not significant
(Table 2). These three observations indicate that
the D315 mutation may be an interesting target for
diagnostics and further research.
Resistant isolates were reported shortly after
the introduction of isoniazid in the 1950s. These
isolates had a significantly reduced level of
virulence in guinea-pigs [27], and were less likely
to result in secondary cases (i.e., transmission) in
population studies [28,29]. The ability of M. tuber-
culosis to persist in mice and guinea-pigs was
shown to depend on the presence of katG or
certain mutations therein [30]; isolates with a
deleted or a mutated and dysfunctional katG that
lacked catalase activity were less virulent and did
not persist in laboratory animals. In contrast, D315
isoniazid-resistant isolates retained 30–40% of
their original catalase activity after site-directed
mutagenesis [19], and it has been shown in mice
that isogenic M. tuberculosis strains with and
Table 1. Associations of Mycobacterium tuberculosis isolates from Dutch and non-Dutch patients with clinical and
laboratory variables
Variable











Previous TB 0.80 (0.63–1.02)
Yes 138 (4.4) 150 (3.6)
No 2979 (95.6) 4038 (96)
Pulmonary TB 0.56 (0.51–0.62)
Yes 2604 (83) 3122 (64)
No 833 (17) 1773 (36)
ZN smear 0.71 (0.62–0.81) 0.69 (0.59–0.81)
Positive 804 (57) 1023 (49)
Negative 597 (43) 1071 (51)
Cluster 0.80 (0.73–0.88) 0.42 (0.35–0.49)
Yes 1843 (54) 2354 (48)
No 1594 (46) 2541 (52)
Beijing strain 1.12 (0.92–1.35)
Yes 199 (5.8) 314 (6.4)
No 3238 (94.2) 4581 (93.6)
Rifampicin-resistant 6.85 (3.19–15.3) 4.63 (1.06–20.0)
Yes 8 (0.23) 77 (1.6)
No 3429 (99.8) 4818 (98.4)
Isoniazid-resistant 3.27 (2.63–4.06) 1.66 (1.13–2.43)
Yes 111 (3.2) 481 (9.8)
No 3326 (96.8) 4414 (90)
D315 2.54 (1.62–3.98)
Yes 40 (36) 283 (59)
No 71 (64) 198 (41)
Streptomycin-resistant 3.26 (2.68–3.96) 1.51 (1.10–2.09)
Yes 139 (4) 591 (12)
No 3298 (96) 4304 (88)
Multidrug-resistant 8.06 (3.36–20.6)
Yes 6 (0.17) 68 (1.4)
No 3431 (99.8) 4827 (98.6)
TB, tuberculosis; ZN, Ziehl–Neelsen; D315, mutation at amino-acid position 315 of katG.
Fig. 2. Age group distribution for Dutch and non-Dutch
tuberculosis patients.
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without the D315 mutation are equally virulent
and persistent [31]. The D315 mutation appears to
interfere less with the catalase and peroxidase
activities of the enzyme than with the isoniazid-
converting activity. The combination of a residual
catalase activity and isoniazid resistance might
explain the success of D315 isolates. This hypo-
thesis is supported further by the reduced trans-
missibility of non-D315 isoniazid-resistant isolates
and the maintained transmissibility of D315 iso-
lates detected in the present, much extended
study.
Although increased clustering among non-
Dutch patients could also be caused by (e.g.) the
Table 2. Associations of isoniazid-sensitive and -resistant Mycobacterium tuberculosis isolates from Dutch and non-Dutch
patients with clinical and laboratory variables
Variable






















Previous TB 1.35 (0.48–3.13) 3.24 (2.15–4.86)
Yes 132 (4.4) 6 (5.8) 114 (3.0) 36 (9.1)
No 2882 (95.6) 97 (94.2) 3679 (97.0) 359 (90.9)
Pulmonary TB 1.05 (0.66–1.68) 1.19 (0.97–1.46)
Yes 2519 (76) 85 (77) 2798 (63) 324 (67)
No 807 (24) 26 (23) 1616 (37) 157 (33)
ZN smear 1.03 (0.56–1.89) 1.55 (1.15–2.09) 1.47 (1.05–2.06)
Positive 775 (57) 29 (58) 900 (48) 123 (59)
Negative 576 (43) 21 (42) 984 (52) 87 (41)
Cluster 1.23 (0.82–1.84) 0.82 (0.68–1.00)
Yes 1778 (53) 65 (59) 2144 (49) 210 (44)
No 1548 (47) 46 (41) 2270 (51) 271 (56)
Beijing strain 1.10 (0.43–2.39) 1.82 (1.31–2.53)
Yes 192 (5.8) 7 (6.3) 264 (6.0) 50 (10)
No 3134 (94.2) 104 (93.7) 4150 (94.0) 431 (90)
RIF-resistant 95.0 (16.6–966) 94.7 (13.4–669) 80.6 (38.6–174) 78.7 (28.7–215)
Yes 2 (0.06) 6 (5.4) 9 (0.2) 68 (14)
No 3324 (99.94) 105 (94.6) 4405 (99.8) 413 (86)
STR-resistant 24.6 (15.7–38.7) 19.3 (12.3–30.3) 12.5 (10.1–15.5) 14.2 (10.1–20.1)
Yes 93 (2.8) 46 (41) 344 (7.8) 247 (51)
No 3233 (97.2) 65 (59) 4070 (92.2) 234 (49)
TB, tuberculosis; ZN, Ziehl-Neelsen; RIF, rifampicin; INH-s, isoniazid-sensitive; INH-r, isoniazid-resistant; STR, streptomycin.
Table 3. Associations of isoniazid-resistant Mycobacterium tuberculosis isolates, with and without a mutation at amino-acid
























Previous TB 0.35 (0.01–3.38) 1.04 (0.49–2.22)
Yes 1 5 22 (9.2) 14 (8.9)
No 35 62 216 (90.8) 143 (91.1)
Pulmonary TB 4.04 (1.21–17.3) 4.81 (1.46–15.9) 1.10 (0.73–1.64)
Yes 36 49 193 (68) 131 (67)
No 4 22 90 (32) 67 (33)
ZN smear 0.78 (0.21–2.79) 1.10 (0.61–2.01)
Positive 12 17 75 (60) 48 (57)
Negative 10 11 51 (40) 36 (43)
Cluster 1.29 (0.54–3.09) 1.67 (1.13–2.46) 1.71 (1.15–2.54)
Yes 25 40 138 (49) 72 (36)
No 15 31 145 (51) 126 (64)
Beijing strain 2.52 (0.40–18.0) 1.55 (0.80–3.04)
Yes 4 3 34 (12) 16 (8.1)
No 36 68 249 (88) 182 (91.9)
RIF-resistant ⁄
multidrug-resistant
3.83 (0.51–43.7) 1.97 (1.09–3.61) 1.92 (1.05–3.50)
Yes 4 2 49 (17) 19 (9.6)
No 36 69 234 (83) 179 (90.4)
STR-resistant 2.82 (1.18–6.82) 3.26 (1.40–7.56) 4.31 (2.87–6.48) 4.27 (2.88–6.33)
Yes 23 23 186 (66) 61 (31)
No 17 48 97 (34) 137 (69)
TB, tuberculosis; ZN, Ziehl-Neelsen; RIF, rifampicin; INH-r, isoniazid-resistant; D315, mutation at amino-acid 315 of katG; STR, streptomycin.
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prevalence of clustered strains in the countries of
origin, the duration of stay in The Netherlands, or
the number of people per household, the presence
of a biological explanation and the findings of the
present study suggest that a causative relation-
ship between the D315 mutation and increased
clustering among isoniazid-resistant isolates is
plausible. The use of a shorter period of 2–3 years
to define clusters would have allowed a more
specific definition of recent transmission, but
could not be used with the data that were
available for analysis.
Interestingly, a study in Spain, in which 180
MDR isolates were characterised, revealed that
the D315 mutation was present in only 25% of
clustered MDR isolates. No data were available
for the non-clustered isolates. In studies in eastern
Europe or southeast Asia with MDR isolates, the
percentage of D315 isolates is usually very high
[32,33]. These differences might be explained by
the lower percentage of immigrants with TB in
Spain (i.e., a higher prevalence of D315 among
immigrants in The Netherlands), and by the
presence of an indigenous MDR strain without
the D315 mutation that is responsible for 29% of
clustered MDR cases [34].
The acquisition of resistance to anti-TB drugs
by mycobacteria is a stepwise process in which
resistant bacteria have an advantage over non-
resistant bacteria in gaining additional resistance.
In the present study, isoniazid-resistant isolates
were more likely to be streptomycin- or rifampi-
cin-resistant, and vice versa (data not shown). An
explanation for the observation that D315 isolates
were more likely to be co-resistant to streptomy-
cin, or to be MDR, than other isoniazid-resistant
isolates may be that mono-resistant unattenuated
mycobacteria (D315 isolates) are, under sub-opti-
mal therapy, more likely to persist and to become
resistant to other agents.
An alternative explanation could be that the
D315 mutation and the additional resistance are
both caused by a common underlying mecha-
nism. One such mechanism might be an increa-
sed tendency to mutation, e.g., caused by a
defect in the DNA repair machinery, as has
been described for the hyper-virulent Beijing
lineage [35]. The observation that certain muta-
tions in rpoB that are associated with resistance
to rifampicin are much more frequent among
D315 isolates than among other rifampicin-
resistant isolates (data not shown) might also
be indicative of the presence of a common
underlying mechanism.
In conclusion, the present work suggests that
screening of mycobacteria for the presence of the
D315 mutation may be a useful tool in developed
countries, both for therapy guidance for individ-
ual patients, and for the surveillance of resistance.
The question as to whether the therapy of indi-
vidual patients should be adjusted immediately
after detection of the D315 mutation in M. tuber-
culosis (preferably directly in clinical material)
remains to be answered.
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